Clinical trial
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
NCT00003760 · The University of Texas Health Science Center at San Antonio, Other · Completed
Key facts
| NCT number | NCT00003760 |
|---|---|
| Title | Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer |
| Official title | A Phase II Trial of MGI 114 in Patients With Advanced Pancreatic Adenocarcinoma |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | National Cancer Institute (NCI) NIH University of Texas Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Enrollment | 3 |
| Start date | Nov 1, 1998 |
| Primary completion | May 1, 2000 |
| Completion | May 1, 2000 |
| First posted | Aug 4, 2004 |
| Last update posted | Aug 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: